General Biotechnology

First to File. First to Profit: The Complete Guide to Paragraph IV Certifications and 180-Day Exclusivity

First-to-File, First-to-Profit: The Real Strategic Value of Paragraph IV + 180-Day Exclusivity
Most people treat Paragraph IV certifications like a legal checkbox—something you file, litigate, and move on from. But in branded pharma, Paragraph IV is le…

First to File. First to Profit: The Complete Guide to Paragraph IV Certifications and 180-Day Exclusivity Read Post »

Uncategorized

Read Their Drug Pipeline Before They Publish It: Competitive Forecasting with Pharmaceutical Patent Intelligence

Before a drug ever hits a press release, the real competition is already in motion.
Most teams only react once a pipeline is public—when a company files a press release, posts trial results, or publishes a slide deck. But in pharma, “public” is often…

Read Their Drug Pipeline Before They Publish It: Competitive Forecasting with Pharmaceutical Patent Intelligence Read Post »

Uncategorized

Pick the Right Patent Or Leave Billions on the Table: The Definitive Guide to the One-Patent-Per-Product Rule and PTE Selection Strategy

Pick the Right Patent—or Leave Billions on the Table: The One-Patent-Per-Product Rule and PTE Selection Strategy
In pharma, the difference between winning and losing isn’t always the science. Often, it’s the paperwork—specifically, which patent you cho…

Pick the Right Patent Or Leave Billions on the Table: The Definitive Guide to the One-Patent-Per-Product Rule and PTE Selection Strategy Read Post »

Uncategorized

Win More 505(b)(2) Business: A guide for CDMOs and specialty labs targeting companies developing 505(b)(2) follow-on drugs

Most 505(b)(2) strategies fail before the first filing—because teams treat it like a regulatory checkbox, not a business model.
If you’re a CDMO, specialty lab, or service provider supporting 505(b)(2) follow-on drugs, you’re not just helping sponsors …

Win More 505(b)(2) Business: A guide for CDMOs and specialty labs targeting companies developing 505(b)(2) follow-on drugs Read Post »

Uncategorized

India’s Drug Patent Clock: The Definitive Guide to How Long Drug Patent Protection Actually Lasts in India

India’s “drug patent clock” isn’t a clock at all—it’s a maze. Here’s how long protection really lasts.
If you’ve ever heard that a drug patent in India “lasts 20 years,” you’ve heard the headline—not the reality.
In practice, the effective protection w…

India’s Drug Patent Clock: The Definitive Guide to How Long Drug Patent Protection Actually Lasts in India Read Post »

Biotechblog
Scroll to Top